Drugs Disributed by SLE
Amphetamines. Dextroamphetamine Sulfate 1.25, 2.5, 5, 7.5 mg, Dextroamphetamine Saccharate 1.25, 2.5, 5, 7.5 mg, Amphetamine Sulfate 1.25, 2.5, 5, 7.5 mg, Amphetamine Aspartate Monohydrate 1.25, 2.5, 5, 7.5 mg. EXT. REL. CAPS.:10/20/30 mg X30. Indiv. dosage at the lowest effect. dose.
Childr.: 6 to 12 years of age: start with 10 mg once daily in the morn.; daily dosage may be adj. in incr. of 5 mg or 10 mg at wkly intervals. Also, pts. may begin with 5 mg once daily in the morn. Max recom. dose for childr. 6 to 12 years of age is 30 mg/day; Adolesc.: Start. dose for adolesc. who are 13 to 17 years of age is 10 mg/day. Dose may be incr. to 20 mg/day after one week if needed. Adlts: recom. dose is 20 mg/day. See prescr. info. for further details.
Attent. deficit hyperact. disor. (ADHD).
C/I: * Adv. arterioscl.*Symptom. cardiovas. dis.
* Moder. to sev. hyperten.* Hyperthyr.
* Glaucoma.* Agitated states.
* Hist. of drug abuse.
* Pts. taking MAOIs, or within 14 days of stopping MAOIs (including linezolid or IV methylene blue), bec. of incr. risk of hyperten. crisis.
*Hypersens.
Tyrosine Kinase Inhibitor. Dasatinib 20, 50, 70, 100 mg. FC Tabs: 60X 20, 50, 70mg,30X 100 mg. Recomm. starting dose for chron. phase CML is 100 mg dasatinib/d. Recomm. starting dose for accel., myeloid or lymphoid blast phase (adv. phase) CML or Ph+ ALL is 140 mg/d. Tmt. until dis. progress. or until no longer toler. by ptt. Dose incr. or reduct. based on ptt. resp. and tolerab.
Tmt. of adlt pts. with:
• Newly diagn. Philadelphia chrom. positive(Ph+ )
chronic myelogen. leukaemia (CML) in the chron. phase.
• Chronic, acceler. or blast phase CML with
resist. or intoler. to prior ther. incl. imatinib mesilate.
• Ph+ ac. lymphoblastic leukaemia(ALL) and lymphoid blast CML with resist. or intoler. to prior ther.
C/I:Hypersens.
EGFR Inhibitor. Gefitinib 250 mg. F.C. TAB.:30. 250 mg (1 tab.)×1/d with / without food. See lit.
Tmt. of adult pts. with local. advanced or metastat. Non‐small cell lung cancer (NSCLC) with activat. mutations of EGFR‐TK.
C/I: Hypersens.
Lact.
Direct Factor Xa Inhibitor. Rivaroxaban 2.5 mg, 10 mg , 15 mg, 20 mg. FC. Tab: 28/30/56/60/100/250 X 2.5/10/15/20 mg Dosage. must be adj. indiv. accord. to pts.med.cond.
Rivaroxaban 2.5 mg, co-admin. with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel, for the prevent. of atherothromb. events in adlt. pts. after ac. coron. syndr. (ACS) with elev. cardiac biomarkers.
Rivar Teva 2.5 mg, co-admin. with (ASA), for the prevent. of atherothromb. events in adlt. pts. with coron. artery dis. (CAD) or symptom. periph. artery disease (PAD) at high risk of isch. events.
Rivaroxaban 10 mg:Prevent. of ven. thromboemb. (VTE) in adlt. pts. undergoing elective hip or knee repl. surg.
Prevent. of recurr. deep vein thromb. (DVT) and pulm. emb. (PE), in adlt.s (follow. complet. of 6 months ther. for DVT or PE)
Rivaroxaban 15 mg and 20 mg: Prevent. of stroke and syst. emb. in adlt. pts. with non-valv. atrial fibrill. with one or more risk factors, such as congest. HF, hypertens., age ≥75 years, diabetes mell., prior stroke or transient isch. attack.
Tmt. of DVT. and PE, and prevent. of recurr. DVT and PE in adults.
C/I: Hypersens.
Act. clin. signif. bleeding.
Lesion or condit., if signif. risk for major bleeding such as: curr. or recent GI ulcerat., malign. neoplasms at high risk of bleeding, recent brain or spinal inj., recent brain, spinal or ophthal. surg., recent intracran. haemorrhage, known or suspect. oesophageal varices, arteriovenous malformat., vasc. aneurysms or major intraspinal or intracerebral vasc. abnormal.
Concom. tmt. with other anticoag. e.g. unfract. heparin (UFH), low MW heparins (enoxaparin, dalteparin, etc.), heparin der (fondaparinux, etc.), oral anticoag. (warfarin, dabigatran etexilate, apixaban, etc.) except under spec. circumst. of switching anticoag. ther. or when UFH is given at doses necess. to maintain
an open central ven. or arter. catheter .
Concom. tmt. of ACS with antiplat. ther. in pts. with a prior stroke or a trans. isch. attack (TIA).
Concom. tmt. of CAD/PAD with ASA in pts. with prev. haemorrhagic or lacunar stroke, or any stroke within a month.
Hepat. dis. assoc. with coagulopathy and clin. relev. bleeding risk incl. cirrhotic pats. with Child Pugh B and C.
Pregn. and breast feed.
DPP-4 Inhibitor. Sitagliptin 25 mg, 50 mg, 100 mg. FC tab 25, 50, 100 mg. Dosage for guid. only: 100 mg once dly.
See ptt's. leaflet
As an adjunct to diet and exercise to impr. glycemic
ctrol. in adults with type 2 diabetes mel. Import. limit. of use: Sitagliptin should not be used in ptts. with type 1 diabetes or for tmt. of diabetic ketoacidosis as it would not be effective.Sitagliptin has not been studied in ptts. with a hist. of pancreat. It is unknown whether these ptts. are at incr. risk for the developm. of pancreat. while on this drug.
C/I:Hypersens.
